Gynecology Book

http://www.fpnotebook.com/

Estrostep

Advertisement

  1. See Also
    1. Oral Contraceptive
    2. Oral Contraceptive Drug Interaction
    3. Oral Contraceptive Selection
    4. Oral Contraceptive Side Effect Management
    5. Oral Contraceptive-Related Uterine Bleeding Management
  2. Preparations (Norethindrone Acetate / Ethinyl Estradiol)
    1. Estrostep (1 / 20 - 30 - 35)
  3. Components
    1. Norethindrone Acetate 1 mg (see preparation above)
    2. Ethinyl Estradiol 20 ug - 30 ug - 35 ug
  4. Effects
    1. Relative Progestational Activity: 1.2 (high)
    2. Estrogenic Activity: 16 (low)
    3. Androgenic Activity: 0.53 (high)
  5. Pill associated problems
    1. Indications to switch to Ortho Novum 1/35
      1. Acne Vulgaris (lower androgen)
    2. Indications to switch to Ortho Cyclen
      1. Increased Appetite (lower Progestin)
      2. Major Depression provoked (lower Progestin)
    3. Indications to switch to Lo/Ovral
      1. Break-through bleed days 1-9 (more Estrogen)
      2. Break-through bleed all of month (more Estrogen)
      3. Menses too light (more Estrogen, less Progestin)
    4. Indications to switch to Loestrin 1.5/30
      1. Libido decreased (more androgen)
      2. Break-through bleed days 10-21 (more Progestin)
      3. Heavy Menses (more Progestin or less Estrogen)
      4. Dysmenorrhea or Menstrual Cramps (more Progestin)
    5. Indications to switch to Loestrin 1/20
      1. Breast Tenderness or engorgement (lower Estrogen)
      2. Headaches (lower Estrogen)
      3. Moodiness (less Estrogen or more Progestin)
      4. Weight gain (less Estrogen or more Progestin)
  6. References
    1. Cerel-Suhl (1999) Am Fam Physician 60(7):2073
    2. Speroff (1993) Obstet Gynecol 81:1034
    3. Dickey (1998) Managing Contraceptive Pill Patients

Estrostep (C0116660)

ConceptsSteroid (T110) , Pharmacologic Substance (T121)
MSHC020416
EnglishEstrostep
SourcesMSH
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree